Recent advances in the treatment of Niemann pick disease type C: A mini-review

Int J Pharm. 2020 Jun 30:584:119440. doi: 10.1016/j.ijpharm.2020.119440. Epub 2020 May 16.

Abstract

Niemann Pick disease Type C (NPC) is a recessive rare disease caused by the mutation on NPC1 and/or NPC2 genes changing the processing of the Low-density proteins (LDL) resulting in an accumulation of lipids in the cells. Until today there is not a cure, the current treatment is based on palliative affairs to reduce the symptoms and prevent its appearance. Among all the treatments proposed the use of cyclodextrins (CDs), nanocarriers which can complex cholesterol, is one of the most useful alternatives. Indeed, for several years 2-hydroxypropyl-β-CD (HPβ-CD) is approved as orphan drug for FDA and EMA to the treatment. However, different CDs based materials are created each year to improve the cholesterol uptake. This review is focused on the novelty of CD based materials for NPC treatment.

Keywords: 2-hydroxypropyl-β-CD; Materials; Niemann Pick disease type C; Rare disease; Review; Treatment.

Publication types

  • Review

MeSH terms

  • Animals
  • Cyclodextrins / therapeutic use*
  • Humans
  • Niemann-Pick Disease, Type C / drug therapy*

Substances

  • Cyclodextrins